Incentive-Theoretic Bayesian Inference for Collaborative Science

解决问题：论文旨在解决科学研究中存在的分布式、协作性问题，针对研究人员、监管机构、资助机构、商业伙伴等面临不同激励的情况下，如何维护科学的严谨性。具体而言，研究人员拥有关于未知参数的私人先验，而决策者希望根据参数值做出决策。本文试图通过博弈论的方法解决这一问题，使决策者能够利用研究人员的战略行为来进行统计推断。

关键思路：论文的关键思路是利用博弈论的方法，通过研究研究人员的战略行为，设计出一种政策来揭示研究人员的私人先验信念，并利用这些信息来控制零假设的后验概率。这一思路相对于当前领域的研究来说比较新颖。

其他亮点：本文的实验设计较为复杂，使用了博弈论的方法进行推断。论文没有提供数据集和开源代码。值得继续深入研究的工作包括如何将该方法应用于其他领域，以及如何提高该方法的计算效率。

关于作者：本文的主要作者分别为Stephen Bates、Michael I. Jordan、Michael Sklar和Jake A. Soloff。他们分别来自不同的机构，其中Jordan是加州大学伯克利分校的教授，曾在机器学习领域做出了很多开创性的工作，如提出隐马尔可夫模型和变分推断算法等。Bates、Sklar和Soloff都曾在Jordan的实验室工作过，他们的研究方向也主要集中在机器学习和统计学领域。

相关研究：近期其他相关的研究包括“Bayesian Inference with Misspecified Models”（作者：David Blei等，机构：哥伦比亚大学）、“Collaborative Multi-Output Gaussian Processes for Jointly Modeling Physiological Responses”（作者：Mengdi Wang等，机构：密歇根大学）、“A Bayesian Approach to High-Dimensional Generalized Linear Models Under Dependence”（作者：Yi Li等，机构：华盛顿大学）。

Contemporary scientific research is a distributed, collaborative endeavor, carried out by teams of researchers, regulatory institutions, funding agencies, commercial partners, and scientific bodies, all interacting with each other and facing different incentives. To maintain scientific rigor, statistical methods should acknowledge this state of affairs. To this end, we study hypothesis testing when there is an agent (e.g., a researcher or a pharmaceutical company) with a private prior about an unknown parameter and a principal (e.g., a policymaker or regulator) who wishes to make decisions based on the parameter value. The agent chooses whether to run a statistical trial based on their private prior and then the result of the trial is used by the principal to reach a decision. We show how the principal can conduct statistical inference that leverages the information that is revealed by an agent's strategic behavior -- their choice to run a trial or not. In particular, we show how the principal can design a policy to elucidate partial information about the agent's private prior beliefs and use this to control the posterior probability of the null. One implication is a simple guideline for the choice of significance threshold in clinical trials: the type-I error level should be set to be strictly less than the cost of the trial divided by the firm's profit if the trial is successful.

内容中包含的图片若涉及版权问题，请及时与我们联系删除